164 related articles for article (PubMed ID: 21590790)
21. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
McGovern A; Chapple AG; Ma C
Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
[TBL] [Abstract][Full Text] [Related]
22. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.
Chapple AG; Thall PF
Pharm Stat; 2018 Nov; 17(6):734-749. PubMed ID: 30112806
[TBL] [Abstract][Full Text] [Related]
23. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
[TBL] [Abstract][Full Text] [Related]
24. Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future Prospects.
Yin Z; Mander AP; de Bono JS; Zheng H; Yap C
JCO Precis Oncol; 2024 Jan; 8():e2300441. PubMed ID: 38181316
[TBL] [Abstract][Full Text] [Related]
25. Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method.
Ji L; Lewinger JP; Krailo M; Groshen S; Conti DV; Asgharzadeh S; Sposto R
Pharm Stat; 2019 Nov; 18(6):659-670. PubMed ID: 31237419
[TBL] [Abstract][Full Text] [Related]
26. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
27. Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.
Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
Stat Med; 2011 Jul; 30(17):2070-80. PubMed ID: 21344472
[TBL] [Abstract][Full Text] [Related]
28. Adaptive dose-finding studies: a review of model-guided phase I clinical trials.
Iasonos A; O'Quigley J
J Clin Oncol; 2014 Aug; 32(23):2505-11. PubMed ID: 24982451
[TBL] [Abstract][Full Text] [Related]
29. Dose-finding design and benchmark for a right censored endpoint.
Andrillon A; Chevret S; Lee SM; Biard L
J Biopharm Stat; 2020 Nov; 30(6):948-963. PubMed ID: 33222634
[TBL] [Abstract][Full Text] [Related]
30. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
31. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
[TBL] [Abstract][Full Text] [Related]
32. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.
Ezzalfani M; Zohar S; Qin R; Mandrekar SJ; Deley MC
Stat Med; 2013 Jul; 32(16):2728-46. PubMed ID: 23335156
[TBL] [Abstract][Full Text] [Related]
33. Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies.
Yin G; Yang Z
Contemp Clin Trials Commun; 2020 Sep; 19():100650. PubMed ID: 32875142
[TBL] [Abstract][Full Text] [Related]
34. Dose-finding designs for cumulative toxicities using multiple constraints.
Lee SM; Ursino M; Cheung YK; Zohar S
Biostatistics; 2019 Jan; 20(1):17-29. PubMed ID: 29140414
[TBL] [Abstract][Full Text] [Related]
35. Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial.
Patel A; Brock K; Slade D; Gaunt C; Kong A; Mehanna H; Billingham L; Gaunt P
BMC Med Res Methodol; 2024 Jan; 24(1):11. PubMed ID: 38218799
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
Iasonos A; Wilton AS; Riedel ER; Seshan VE; Spriggs DR
Clin Trials; 2008; 5(5):465-77. PubMed ID: 18827039
[TBL] [Abstract][Full Text] [Related]
37. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
de Haan R; van Werkhoven E; van den Heuvel MM; Peulen HMU; Sonke GS; Elkhuizen P; van den Brekel MWM; Tesselaar MET; Vens C; Schellens JHM; van Triest B; Verheij M
BMC Cancer; 2019 Sep; 19(1):901. PubMed ID: 31500595
[TBL] [Abstract][Full Text] [Related]
38. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
Ursino M; Biard L; Chevret S
Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
[TBL] [Abstract][Full Text] [Related]
39. Specifications of a continual reassessment method design for phase I trials of combined drugs.
Wages NA; Conaway MR
Pharm Stat; 2013; 12(4):217-24. PubMed ID: 23729323
[TBL] [Abstract][Full Text] [Related]
40. The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM.
Koopmeiners JS; Wey A
J Biopharm Stat; 2017; 27(6):1028-1042. PubMed ID: 28340333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]